Condition: Glioblastoma · Sponsor: Global Coalition for Adaptive Research
Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM. All institutions are enrolling Newly Diagnosed participants. Institutions also enrolling Recurrent participants are marked with an asterisk (\*).
This description comes directly from the study's public registry record.
Patient Information · 310-598-3199 · patientinfo@gcaresearch.org
Rachel Rosenstein-Sisson · RRosenstein.Sisson@GCAResearch.org
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| University of California, San Diego | La Jolla, California, United States | Recruiting |
| Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute | Los Angeles, California, United States | Recruiting |
| University of California, Los Angeles | Los Angeles, California, United States | Recruiting |
| St. Joseph Hospital | Orange, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Stanford Cancer Center | Stanford, California, United States | Completed |
| University of Colorado Denver | Aurora, Colorado, United States | Recruiting |
| Yale Cancer Center / Smilow Cancer Hospital* | New Haven, Connecticut, United States | Recruiting |
| Mayo Clinic Cancer Center | Jacksonville, Florida, United States | Completed |
| Sylvester Comprehensive Cancer Center* | Miami, Florida, United States | Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
+ 51 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03970447